Novo Nordisk alleges fraud after $1.3 billion deal to buy hypertension drug from KBP Biosciences
Novo Nordisk is seeking up to $830 million in damages from KBP Biosciences, according to a ruling by a Singapore court, as ...
The Independent Singapore41m
Singapore biotech tycoon Huang Zhenhua’s assets frozen in US$830 million legal battle with pharma giant
SINGAPORE: Pharmaceutical giant Novo Nordisk is taking legal action in a Singapore court, seeking damages of up to US$830 ...
FierceBiotech3d
Novo Nordisk to sue KBP Biosciences over alleged fraudulent claims on kidney disease drug
After its potential kidney disease drug went down in flames late last year, Novo Nordisk is pinning the blame on alleged ...
Singapore biotech tycoon Huang Zhenhua has assets frozen over $1.1 billion suit by pharma giant
Wegovy maker Novo Nordisk is accusing Mr Huang and his firm of fraudulent claims over a hypertension drug. Read more at ...
pharmaphorum3d
When licensing deals go bad - Novo sues KBP Bio for $830m
A lawsuit filed in the Singapore International Commercial Court is seeking $830 million in damages from KBP, with Novo ...
FiercePharma1d
Fierce Pharma Asia—Novo Nordisk's fraud accusation; AstraZeneca's China deal; Ono's FDA nod
Novo Nordisk alleges Singaporean biotech KBP Biosciences made misleading statements before the two firms inked a licensing ...
Scandasia.com2d
Novo Nordisk sues Singapore biotech firm over $1.3 billion acquisition dispute
Novo Nordisk, the Danish pharmaceutical giant, has filed a lawsuit against Singapore-based KBP Biosciences and its founder, ...
Singapore biotech tycoon Huang Zhenhua has assets frozen over US$830mil suit by pharma giant
Pharmaceutical giant Novo Nordisk is seeking as much as US$830 million (S$1.1 billion) in damages in an application to a ...